{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:25:13Z","timestamp":1747196713107,"version":"3.40.5"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:p>Currently, intravitreal bevacizumab is widely used for patients with intraocular neovascular disorders and macular edema. There are few studies about the effects of bevacizumab on anterior segment parameters and human cornea. The aim of this study was to evaluate the effects of intravitreal injection of bevacizumab on anterior chamber and central corneal thickness (CCT) during 3 months follow-up, using anterior segment optical coherence tomography. This longitudinal study was included 40 eyes of 20 patients. Patients received an intravitreal injection of 1.25\u2009mg\/0.05\u2009mL bevacizumab. Anterior segment optical coherence tomography images were obtained and measurements were compared including angle opening distance and trabeculo-iris space area at 750\u2009mm from the scleral spur, iris volume, anterior chamber volume, and CCT. Intraocular pressure (IOP) was also measured by Goldmann applanation tonometry. All parameters were measured before injection, 24 hours and 3 months after the last intravitreal injection. The mean age of patients was 61.38\u2005\u00b1\u20059.92 years. Ten patients (52.6%) were male. The mean number of injections was 3.3\u2005\u00b1\u20051.8. Anterior chamber volume, temporal and nasal angles of angle opening distance 750, and trabeculo-iris space area 750 were not significantly changed (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u2005.05). No significant difference was observed in mean IOP before injection and 24 hours and 3 months after injection (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.84 and .08, respectively). The difference in mean of iris volume, before, 24 hours and 3 months after injection was significant (<jats:italic toggle=\"yes\">P<\/jats:italic> value\u2005=\u2005.016). CCT was increased 24 hours and 3 months after injection compared to pre-injection (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.008 and .03). Multiple intravitreal injections of bevacizumab significantly increased CCT 24 hours and 3 months after injection. Bevacizumab has also no significant effect on anterior chamber angle and IOP.<\/jats:p>","DOI":"10.1097\/md.0000000000041994","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T22:26:09Z","timestamp":1746483969000},"page":"e41994","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Anterior segment changes in nonproliferative diabetic patient with macular edema treated by intravitreous bevacizumab injection"],"prefix":"10.1097","volume":"104","author":[{"given":"Elham","family":"Bakhtiari","sequence":"first","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Abrishami","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahideh","family":"Nouzari","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faezeh","family":"Saffari","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5909-5856","authenticated-orcid":false,"given":"Rahim","family":"Saffari","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250513","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/jop.2009.0076","article-title":"Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.","volume":"26","author":"Adelman","year":"2010","journal-title":"J Ocular Pharmacol Therap"},{"key":"R2-20250513","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R3-20250513","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"R4-20250513","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study.","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"R5-20250513","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/IAE.0b013e3180ed458d","article-title":"Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.","volume":"27","author":"Priglinger","year":"2007","journal-title":"Retina"},{"key":"R6-20250513","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1097\/IAE.0b013e318217373c","article-title":"Intraocular pharmacokinetics after a single intravitreal injection of 1.5\u2009mg versus 3.0\u2009mg of bevacizumab in humans.","volume":"31","author":"Meyer","year":"2011","journal-title":"Retina"},{"key":"R7-20250513","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00006982-200603000-00001","article-title":"Testing intravitreal toxicity of bevacizumab (Avastin).","volume":"26","author":"Manzano","year":"2006","journal-title":"Retina"},{"key":"R8-20250513","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.ophtha.2012.06.037","article-title":"Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.","volume":"119","author":"Epstein","year":"2012","journal-title":"Ophthalmology"},{"key":"R9-20250513","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol (Chicago, Ill. : 1960)"},{"key":"R10-20250513","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ajo.2008.06.002","article-title":"Effect of bevacizumab on human corneal endothelial cells: a six-month follow-up study.","volume":"146","author":"Chiang","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R11-20250513","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.","volume":"41","author":"Philipp","year":"2000","journal-title":"Investigative Ophthalmol Visual Sci"},{"key":"R12-20250513","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/IAE.0000000000001018","article-title":"Dynamic changes of the anterior chamber angle produced by intravitreal anti-vascular growth factor injections.","volume":"36","author":"Wen","year":"2016","journal-title":"Retina"},{"key":"R13-20250513","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00061198-200304000-00013","article-title":"Possible mechanisms of primary angle-closure and malignant glaucoma.","volume":"12","author":"Quigley","year":"2003","journal-title":"J Glaucoma"},{"key":"R14-20250513","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2013.11.029","article-title":"Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.","volume":"121","author":"Bakri","year":"2014","journal-title":"Ophthalmology"},{"key":"R15-20250513","first-page":"58. e1","article-title":"Acute angleclosure glaucoma complicating an intravitreal injection of bevacizumab.","volume":"32","author":"Semoun","year":"2009","journal-title":"J Fr Ophtalmol"},{"key":"R16-20250513","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3109\/02713683.2014.888452","article-title":"Short term effects of intravitreal bevacizumab on cornea and anterior chamber.","volume":"39","author":"G\u00fcler","year":"2014","journal-title":"Curr Eye Res"},{"key":"R17-20250513","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/jovr.jovr_257_17","article-title":"Effect of intravitreal bevacizumab injection on corneal in vivo biomechanics: a pilot study.","volume":"14","author":"Shoeibi","year":"2019","journal-title":"J Ophthalmic Vis Res"},{"key":"R18-20250513","first-page":"25158414221133772","article-title":"The short-term effects of intravitreal bevacizumab injection on intraocular pressure, cornea, iridocorneal angle, and anterior chamber.","volume":"14","author":"Gumus","year":"2022","journal-title":"Ther Adv Ophthalmol"},{"key":"R19-20250513","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3109\/02713683.2014.888452","article-title":"Short-term effects of intravitreal bevacizumab on cornea and anterior chamber.","volume":"39","author":"G\u00fcler","year":"2014","journal-title":"Curr Eye Res"},{"key":"R20-20250513","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","article-title":"Safety profile of bevacizumab on cultured human corneal cells.","volume":"26","author":"Yoeruek","year":"2007","journal-title":"Cornea"},{"key":"R21-20250513","doi-asserted-by":"crossref","first-page":"504","DOI":"10.5301\/ejo.5000241","article-title":"Changes in anterior segment morphology after intravitreal injection of bevacizumab and bevacizumab\u2013triamcinolone acetate combination.","volume":"23","author":"Alkin","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"R22-20250513","first-page":"211","article-title":"Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study.","volume":"6","author":"Sobaci","year":"2013","journal-title":"Int J Ophthalmol"},{"key":"R23-20250513","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/IAE.0b013e31823f0c95","article-title":"A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.","volume":"32","author":"Wehrli","year":"2012","journal-title":"Retina"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T22:02:17Z","timestamp":1747173737000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":23,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041994","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2025,5,2]]}}}